Fast-Growing Non-Toxic Nail Salon Franchise Partners With Fighting Pretty to Pamper With Purpose

DENVER, Oct. 10, 2024 /PRNewswire/ — Frenchies Modern Nail Care, a fast-growing national non-toxic nail salon franchise, is thrilled to announce a collaboration with the non-profit organization Fighting Pretty to present “Bubbles and Beauty,” a special event taking place at participating franchises across the nation the week of October 14, 2024. This event aligns perfectly with Breast Cancer Awareness Month, offering a day of complimentary pampering for women battling breast cancer.

Beauty and Bubbles aims to empower these courageous women, providing them with a much-needed respite and a chance to connect with fellow breast cancer fighters. Attendees will leave feeling rejuvenated, supported, and even more resilient in their battle against this devastating disease.

A Survivor’s Story

Kay, a 55-year-old mother of two and a breast cancer survivor, epitomizes the spirit of resilience. Diagnosed with an aggressive form of breast cancer three years ago, Kay has fought her way through several surgeries, including a double mastectomy, as well as multiple rounds of chemotherapy, and extensive medication. 

“When I heard about ‘Bubbles and Beauty’ through Fighting Pretty, I was so excited,” shares Kay. “The focus of my life has been on fighting cancer from the inside, often neglecting my external appearance. This event offers me the chance to feel beautiful again.”

According to BreastCancer.Org:

• 1 in 8 women in the United States will be diagnosed with breast cancer in her lifetime.
• In 2024, an estimated 310,720 women will be diagnosed with breast cancer in the U.S., making it the most common cancer among American women.  
• Every two minutes, a woman in the U.S. is diagnosed with the disease.

“The physical toll of breast cancer treatments can severely impact a woman’s self-esteem,” says Erica Upshur, Vice President of Marketing of Head to Toe Brands, a beauty and wellness platform of The Riverside Company that includes Frenchies Modern Nail Care. “Frenchies Modern Nail Care and Fighting Pretty are committed to uplifting these brave women by offering them a beauty boost. And, given the immunocompromised state of many breast cancer patients, Frenchies is the ideal venue for this event.”

Frenchies studios exceed state licensing standards when it comes to cleanliness. This includes a state-of-the-art personal ventilation system at each station, ensuring the highest level of safety for all attendees.

To learn more about Frenchies Modern Nail Care, visit https://frenchiesnails.com/.

To learn more about franchising opportunities with Frenchies Modern Nail Care, visit https://frenchiesnails.com/own-a-frenchies/.  

About Frenchies Modern Nail Care

Founded in 2014 by franchise experts, Frenchies was created based on the belief that by providing a higher quality experience for guests and nail professionals they will raise the industry standards for nail services. Frenchies leverages the latest nail and beauty industry technology, uses only high-quality professional and retail products, and ensures an unparalleled guest experience at every studio by providing a comprehensive training model. In their local markets, Frenchies franchisees provide a safe workspace and a rewarding career opportunity for studio employees.

Frenchies was acquired by global private equity firm, The Riverside Company, and is now a part of their Head to Toe Brands portfolio enjoying the benefits of leveraging talent and resources across multiple fast-growing beauty service franchises.

In 2017, Frenchies began franchising and now covers 25 locations across the nation. For more information on Frenchies, visit frenchiesnails.com.

Media Contact:
Nancy Bostrom | 919.459.8163 |  nbostrom@919marketing.com

SOURCE Frenchies

https://prnmedia.prnewswire.com/news-releases/frenchies-modern-nail-care-hosts-bubbles-and-beauty-events-for-breast-cancer-warriors-302273043.html

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more

EAGAN, Minn., Oct. 10, 2024 /PRNewswire/ — Prime Therapeutics LLC (Prime) continues to position itself as a leader in the pharmacy solutions industry by presenting 10 research studies at the 2024 Academy of Managed Care Pharmacy (AMCP) Nexus event, Oct. 14–17 in Las Vegas.

Using integrated medical and pharmacy claims data, researchers from across the organization evaluated real-world drug utilization, managed care pharmacy programs, and associated cost of care for a range of topics, including adherence/persistence data of glucagon-like peptide-1 (GLP-1) agonist drug therapies for weight loss, the impact of social determinants of health (SDOH) on asthma and diabetes drug treatment, and more.

“At Prime, we aspire to be an icon for innovation in pharmacy solutions, and it’s our managed care pharmacy research that brings this to life and sets us apart in our industry,” said Steve Cutts, senior vice president of specialty and clinical solutions. “We are proud of our researchers for their hard work forging a path toward better health outcomes and reduced costs for our members.”

The following studies will be presented at this year’s event, further exemplifying Prime’s efforts to save, simplify and support every piece of the pharmacy experience:

Save: Making medications more affordable

• Evaluating the 10-Year Impact of an Immunoglobulin Utilization Management and Dose Optimization Program in the Managed Care Setting
  The recipient of a gold award, this study analyzed the impact of immunoglobulin dose optimization programs in a managed care setting.
• Impact of a Pharmacist-Facing Clinical Management Tool: Identification and Management of Cumulative Oversupply in Pharmacy Benefit Dupilumab Utilizers
  This study analyzed managed care pharmacist outreach through Prime’s HighTouchRx^® product to reduce drug therapy cost of the inflammation drug dupilumab (Dupixent^®).
• Dosage Form and Product Strength Optimization: Containing the Cost of Ibrutinib Therapy Through a Pharmacist-Facing Clinical Management Tool 
  This study evaluated the effectiveness of Prime’s HighTouchRx product for improving cost containment associated of ibrutinib (Imbruvica^®) for oral oncology therapy.
• Real-World Extended Dosing Assessment for Eye(s) New to Faricimab-svoa Therapy
  This study assessed extended dosing of faricimab-svoa (Vabysmo^®) therapy for retinal diseases.

Simplify: Delivering an easy, transparent experience

• Methodological Framework for Propensity Adjusted Benchmarks for Pharmacy Key Performance Indicators
  The purpose of the study was to create a methodological framework for using propensity score weighting to adjust for varying risk profiles when comparing an index group to a benchmark group with a similar risk profile on pharmacy key performance indicators.
• Promoting Health Equity Through Enhanced, Personalized Digital Outreach
  This study analyzed engagement and Medicare health plan performance among Spanish-speaking populations.

Support: Helping people achieve better health

• Real-World Adherence and Persistence to Glucagon-Like Peptide-1 Receptor Agonists at Two Years among Non-Diabetic Obese Commercially Insured Adults
  The recipient of a silver award, this study is part of Prime Therapeutics’ ongoing real-world study of individuals who newly started GLP-1 drugs for weight loss.
• Real-World Case Series Study of Spinal Muscular Atrophy Pediatric Patients Treated with Onasemnogene Abeparvovec (Zolgensma)
  The recipient of a silver award, this study researched real-world spinal muscular atrophy Zolgensma^® gene therapy treatment outcomes.
• Leveraging Publicly Available SDOH Measures to Segment Members and Quantify Differences in Diabetic Medication Adherence: A Latent Profile Analysis
  This study looked at patterns in ZIP codes across the United States and SDOH measures to identify medication adherence for patients with diabetes. 
• Unlocking Public Health Insights: Leveraging Air Quality Data to Develop Social Determinants of Health Metrics Linked to Asthma Medication Ratio
  This study explored how researchers can use SDOH measures to evaluate the treatment of asthma among affected populations.

Prime researchers also will participate in several on-stage sessions during 2024 AMCP Nexus. Additional information on these sessions can be found on the AMCP Nexus agenda.

“Prime’s specialty programs focus on the member first to promote the highest quality care in the most cost-efficient manner, which is why we are proud to deliver the keynote on Specialty Pharmaceuticals in Development at AMCP Nexus,” Cutts added. “We are excited to showcase our research with our peers and illustrate how Prime can reimagine pharmacy solutions.”

For more information on the studies listed above and additional insights from the event, visit the Prime newsroom.

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com 

Contact:
Alex Cook
Manager, Public Relations
612.777.4217
Alex.Cook2@PrimeTherapeutics.com

SOURCE Prime Therapeutics LLC

https://prnmedia.prnewswire.com/news-releases/prime-therapeutics-bolsters-its-position-as-industry-leader-with-10-research-studies-at-amcp-nexus-2024-302272349.html

SALT LAKE CITY, Oct. 10, 2024 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced positive data from its qEEG study of its oral brexanolone, a proprietary bioidentical NAS being developed for the treatment of post-partum depression (PPD). Changes in spectral power (a quantitative measure of the strength or intensity of specific brain wave frequencies) are frequently used to characterize the effects of drug candidates and may have utility in indication and dose selection in CNS clinical trials. The results indicate robust central nervous system (CNS) activity of oral brexanolone, with concentration- and time-dependent post-dose changes in qEEG. These results confirm GABA_A positive allosteric modulation and support future development of oral brexanolone in neuropsychiatric indications.

“We are pleased with the qEEG results that confirm target engagement of oral bioidentical brexanolone, which suggests potential utility in treating numerous psychiatry indications, including depression and anxiety, and neurology indications such as essential tremor and epilepsy,” said Dr. Mahesh Patel, President and CEO of Lipocine Inc. “These positive biomarker results and favorable safety profile support further development of oral brexanolone.”

This Phase 1 study evaluated qEEG spectral power changes after administration of oral brexanolone. Healthy postmenopausal females (N=12) were administered single doses of oral brexanolone. EEG recordings and blood samples were collected pre- and post-dose (2, 4 and 12 hours). EEG recordings were obtained using a wireless, 19-electrode EEG monitoring device (Zeto Inc., Santa Clara, CA). Spectral analysis was performed and EEG band amplitudes were analyzed for the oscillatory spectra. Pre-dose-adjusted spectral power values at each single-electrode location were determined for each post-dose timepoint.

Following a single clinically relevant dose of oral brexanolone, subjects showed mean changes in all oscillatory spectral power bands. As shown in Fig. 1, theta and alpha1 band power were significantly increased in posterior cortical regions, while alpha2 band power decreased. There was considerable beta band amplitude increase, including significant increase in beta2 amplitude across all cortical brain areas Most of the treatment-related EEG changes were rapid occurring as early as 2 hours, with maximum and significant mean contrast values at 4 hours post dose (consistent with T_max) with appreciable effects lasting 12 hours post-dose.

The observed qEEG changes following oral brexanolone administration are consistent with therapies effective in managing depression, anxiety, tremor, and seizures.^1-5

Oral brexanolone was well-tolerated in this Phase 1 study. The safety profile was consistent with safety data from clinical studies previously conducted by Lipocine with minimal CNS depressant effects.

Lipocine plans to present the additional details and analyses from this EEG study at upcoming scientific meetings.

About Quantitative Electroencephalogram (qEEG)

Quantitative Electroencephalogram (qEEG) is an advanced neuroimaging technique used to measure electrical activity in the brain with a high degree of precision and detail.  qEEG uses mathematical and statistical methods to analyze the electrical signals generated by the brain and convert them into quantitative metrics. By translating these signals into a digital format, qEEG allows for the identification and assessment of specific brain wave frequencies — such as delta, theta, alpha, beta, and gamma waves — associated with different states of cognition, emotion, and behavior. This analysis allows researchers to detect subtle changes in brain function that may be induced by a drug, providing important insights into its mechanism of action. In the context of drug development, qEEG is used to evaluate the effect of new therapies on the central nervous system (CNS) by monitoring shifts in brain wave patterns that correlate with therapeutic outcomes. This helps determine whether the drug is acting on the desired neural circuits, provides early evidence of efficacy, and may support dose selection for future clinical trials.

About Lipocine

Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products.  Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships.  Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.

Lipocine’s clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis.  Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of non-cirrhotic NASH.  TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.

Forward-Looking Statements
This release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product development efforts, our strategic plans for developing products, our ability to monetize product candidates, including through entering into partnering arrangements, our product candidates and related clinical trials, the achievement of milestones within and completion of clinical trials, the timing and completion of regulatory reviews, outcomes of clinical trials of our product candidates, and the potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets, the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, and other risks detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

1. Meltzer-Brody et al. Lancet 2018; 392(10152): 1058-1070.
2. Buchsbaum et al. Biol Psychiatry 1985; 20(8): 832-842.
3. Ibanez et al. Plos One 2014; 9(3): e93159.
4. Huang and Shen Clin Electroencephalography 1994; 24(4): 179-187
5. Biondi et al. Sci Rep 2022; 12(1): 1919.

SOURCE Lipocine Inc.

https://prnmedia.prnewswire.com/news-releases/lipocine-announces-positive-oral-brexanolone-quantitative-eeg-results-302272247.html

• Strategic Partnership: Streamlined, single-vendor solution improves diagnostic accuracy, boosts efficiency, and enables reliable turnaround times in gastrointestinal (GI) clinical trials.
  
• Advanced GI Solutions: Enhances trial efficiency with AI-powered solutions, including reading for ulcerative colitis (UC) from Clario and histopathology services from PathAI.
  
• Integrated Workflow: Combines endoscopic and histopathology endpoints with simplified processes for CROs, sponsors, and investigational sites.

PHILADELPHIA, Oct. 10, 2024 /PRNewswire/ — Clario, a leading provider of endpoint data solutions to the clinical trials industry, is excited to announce a strategic partnership with PathAI, a leader in AI-powered digital pathology solutions aimed at improving diagnostic accuracy and efficiency. This collaboration offers a single-vendor solution for efficient anatomical pathology services and next-generation video endoscopy analysis.

This co-delivery model streamlines endoscopic and histopathology endpoints to improve efficiency in global GI studies. CROs and sponsors will benefit from an end-to-end process that covers training, logistics, tissue processing, slide digitization, image analysis, and data transfers all with the medical and scientific oversight of our experts. Sites will experience simplified workflows with improved training, reporting, and document management.

“At Clario we have long been at the forefront of supporting GI clinical trials, and we are excited to augment our strengths with PathAI’s capabilities in the area of discovery and patient care,” said Marcela Vieira, M.D., Clario’s Medical Director of Gastroenterology. “The combination of endoscopy and histopathology promises to unlock new avenues for clinical research, and we are proud to be in this leadership position with our partners at PathAI.”

Clario has extensive experience in GI trials, having supported over 130 studies through advanced imaging solutions like endoscopy, MRI, and ultrasound. Their scientists and technologies help reduce site burden and enhance trial efficiency with AI-supported reading for UC and HD-video endoscopy support.

PathAI bolsters the partnership with its expert GI pathologist network and cutting-edge anatomical pathology services while optimizing specimen handling and histological assessments. Their AI-powered tools enhance UC assessment, minimize variability in histological scoring, and expedite biomarker discovery.

“We’re thrilled to partner with Clario to provide a cutting-edge solution for IBD clinical trials,” said Matt Grow, Chief Business Officer & President of Biopharma at PathAI. “Our collaboration will offer an integrated approach in histology and endoscopy for assessing therapeutic efficacy, accelerating biomarker discovery and therapy development in IBD.”

About Clario

Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac solutions, medical imaging, precision motion, and respiratory endpoints.

For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported over 26,000 clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.

For more information, visit Clario.com or follow on LinkedIn.

About PathAI

Headquartered in Boston, PathAI is the only AI-focused technology company providing comprehensive precision pathology solutions, from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with over 15 million annotations, its AI-powered models optimize pathology sample analysis, improving efficiency and accuracy in interpretation while gauging therapeutic efficacy and accelerating drug development for complex diseases.

For more information, visit pathai.com 

Media Contact:
media@clario.com

SOURCE Clario

https://prnmedia.prnewswire.com/news-releases/clario-and-pathai-collaborate-to-deliver-integrated-solution-for-gi-clinical-trials-302271866.html

ANN ARBOR, Mich., Oct. 10, 2024 /PRNewswire/ — Today, Censys, the leading Internet Intelligence Platform for Threat Hunting and Attack Surface Management, published its findings on the 2024 Global State of Internet | Healthcare Assets Exposed on Public-Facing Networks. Censys identified over 14,000 distinct IP addresses exposing healthcare data and devices to the internet – with nearly 50% of hosts located in the United States. Considering healthcare and public health organizations are the top critical infrastructure sectors targeted by ransomware attacks, Censys identified exposures across some of the largest urban healthcare systems to smaller, rural environments.

Regardless of institutional size, this rise in ransomware incidents demonstrates the importance of protecting patient data from malicious threat actors – such as medical history, social security information, insurance information and more.

Censys’ comprehensive internet visibility and scanning capabilities enabled the research team to identify significant devices and record exposures across the globe, including:

• Medical Images: Digital Imaging and Communications in Medicine (DICOM)-enabled servers are the most commonly exposed healthcare technology. 36% percent of all Censys identified exposures are DICOM services. These are used for handling potentially sensitive medical images – such as X-rays, ultrasounds, computed technology (CT) scans, magnetic resonance imaging (MRIs), etc.
• Healthcare & Public Health Vendors: While many software vendors were represented across healthcare assets, one vendor accounted for over 90% of the 4,000 publicly available electronic medical record systems Censys observed. About 11% of the applications identified across all asset categories were open-source software.
• Countries & Regions: Due to population and widespread adoption of healthcare technology, the U.S. leads with the most publicly available applications, with nearly 7,000 currently online across different networks. Censys detected only 200 publicly available applications in the United Kingdom—possibly an indication of a more centralized healthcare infrastructure.

“In this age of increasing ransomware attacks, internet-connected healthcare applications should be safeguarded from the public internet – it’s clear that patient data continues to be a valuable target for malicious actors,” said Himaja Motheram, security researcher at Censys. “Our mission at Censys is to provide visibility into the potential security gaps that tend to go overlooked – these types of devices and systems are often developed without security in mind.”

To prevent data breaches and attacks, effective attack surface management is crucial for hospitals and organizations that handle medical data – but many lack the resources to analyze their exposed assets in an actionable way. Censys’ analysis is the first in-depth overview of its kind, providing a global view of the exposure of Internet of Healthcare Things (IoHT) on public-facing networks, through detailed breakdowns by device type, vendor, country and more.

By leveraging Censys’s monitoring capabilities, healthcare organizations can proactively identify and mitigate exposures and vulnerabilities before they lead to data breaches or ransomware attacks. For more information, the full research report can be found here: https://censys.com/state-of-internet-of-healthcare-things.

Censys’s mission is to make the internet a more secure place for everyone. This drives our commitment to responsible disclosure when identifying exposed systems – particularly those in the critical infrastructure sector. As part of this research, Censys made every effort to attribute each device or web asset to the appropriate organization(s) to notify the relevant stakeholders.

About Censys

Censys, Inc. is the leading Internet Intelligence Platform for Threat Hunting and Attack Surface Management. Founded in 2017 in Ann Arbor, Michigan, Censys provides organizations with the most comprehensive real-time view of Internet infrastructure. Customers like Google, Cisco, Microsoft, Samsung, Swiss Armed Forces, the U.S. Department of Homeland Security, Cybersecurity & Infrastructure Security Agency, and over 50% of the Fortune 500 rely on Censys for a real-time, contextualized view into their internet and cloud assets. At Censys, you can be yourself. We like it that way. Diversity fuels our mission, and we are committed to inclusion across race, gender, age and identity. To learn more, visit censys.com and follow Censys on Twitter, Mastodon and LinkedIn.

SOURCE Censys

https://prnmedia.prnewswire.com/news-releases/censys-finds-over-14-000-healthcare-devices-and-records-exposed-to-the-internet-302272394.html

Hosted by Digital Health News (DHN) in collaboration with IIIT-Bangalore, CHIME India, 100X.VC, ScaleHealthTech, and program partner Ninth Dimension, the event emphasized the role of technology in transforming patient care. Karnataka Health Minister Dinesh Gundu Rao, the event’s chief guest, praised the platform for fostering innovation among startups. He remarked, “At the government level, we are looking at solutions that can improve care, reduce costs, and be implemented at a larger scale.”

Over 200 startups entered the challenge, with 14 advancing to the pitch stage. The top five showcased their solutions on demo day, judged by:

• Dr. Lakshmi Jagannathan, CEO, Innovation Centre, IIIT-B
• Mr. Feby Abraham, Chief Strategy & Innovation Officer, Memorial Hermann Health System
• Dr. Girish Kulkarni, Chairperson, CHIME India
• Vishnu Saxena, Founder & CEO, DHN and ScaleHealthTech
• Sanjay Mehta, Founder & Partner, 100X.VC
• Dr. Ganesh Hiregoudar, Director, TSB OTE Engineering, Dell Technologies

MedySeva, a telemedicine platform for rural healthcare, won the challenge. Runners-up included MicroHeal, chronic gut conditions management platform, and Marbles Health, an AI-driven mental health startup. Other notable finalists were Janitri (maternal health monitoring) and Moss.ai (AI-driven clinical decision support).

Vishnu Saxena, Founder and CEO of DHN, celebrated the participants’ courage, saying, “Innovation knows no boundaries, and it requires great courage to launch a startup. At DHN, our goal is to reimagine India’s healthcare by connecting innovative startups with hospitals where patients ultimately benefit.”

Dr. Debabrata Das, Director of IIIT-Bangalore, highlighted India’s dynamic healthtech landscape, noting, “India’s healthcare startup ecosystem is evolving quickly, with 7-10% of startups in health and over 7,000 health tech ventures nationwide.”

The event was a key moment for India’s healthtech community, bringing together startups, healthcare leaders, and innovators to shape the future of healthcare technology.

About DHN

Digital Health News (DHN) is India’s first digital health news platform and a trusted source for HealthTech News, Insights, Trends and Policy. Launched by Industry recognized HealthTech Leaders, DHN provides in-depth data analysis and covers most impactful news across entire ecosystem including- technology, Innovation, startups, hospitals, health insurance, govt policies, pharmaceuticals and biotech. DHN promotes collaboration through forums, webinars, and podcasts, empowering leaders in the digital health ecosystem India and abroad.

CONTACT: Arti Ghargi, Email: Info@scalehealthtech.com

https://prnmedia.prnewswire.com/news-releases/dhn-healthtech-innovation-challenge-2024-medyseva-takes-the-top-spot-karnataka-health-minister-dinesh-gundu-rao-applauds-healthcare-innovation-302271044.html

TORONTO, Oct. 9, 2024 /PRNewswire/ – Healthcare leaders are under increasing pressure to adopt AI technologies that can enhance patient care, streamline operations, and drive better outcomes. They are further challenged to effectively navigate the complex and crowded AI vendor space while evaluating various features and mitigating risks. To help healthcare leaders meet the demanding needs and expectations of the industry, Info-Tech Research Group has published its latest blueprint, Explore Healthcare Enterprise Large Language Model Solutions. The new resource provides IT leaders in the healthcare industry with the tools and insights necessary for assessing AI capabilities, ensuring strategic adoption, and ultimately improving healthcare outcomes through effective LLM solutions.

“The advent of generative AI (Gen AI) solutions, driven by the recent surge in AI capabilities, has sparked considerable interest among healthcare organizations and vendors,” says Sharon Auma-Ebanyat, research director at Info-Tech Research Group. “The healthcare Gen AI field is rapidly advancing, with many vendors claiming that their AI features can tackle healthcare challenges. However, this market saturation complicates the process of navigating potential vendors and determining desired features.”

Info-Tech’s latest resource for the healthcare industry highlights that healthcare IT leaders must access detailed insights into LLM features that can provide real value while addressing key pain points. However, they must contend with the challenges organizations face in navigating an increasingly saturated AI vendor landscape, where every vendor promises solutions to healthcare’s most pressing issues. These obstacles are further exacerbated by the difficulty of adopting generative AI solutions due to budget constraints and the absence of clear strategic frameworks in the industry. The resource underscores that many vendors fail to align their AI tools with the specific operational needs of healthcare institutions, making implementation, configuration, and support more challenging.

In the blueprint, the firm also addresses the privacy risks posed by the data used to train LLMs, which often includes sensitive personal patient information. When used in biomedical applications, LLMs can further pose privacy concerns, as they may have access to detailed patient characteristics.

To guide healthcare IT leaders in tackling the challenges of vendor selection, Info-Tech’s Explore Healthcare Enterprise Large Language Model Solutions outlines three key steps:

• Step 1: Understand key use cases that align with the organization’s objectives, patient needs, and the unique challenges of LLMs.
• Step 2: Develop weighted evaluation criteria to assess vendors, ensuring they align with the organization’s needs and responsible AI practices.
• Step 3: Assess and review AI features and key vendor offerings.

Info-Tech’s comprehensive resource equips healthcare IT leaders with essential insights to navigate the complex AI vendor landscape. By effectively leveraging LLMs, healthcare professionals can make more informed decisions, improve diagnoses and treatment plans, and deliver value through cost savings, revenue optimization, and operational efficiency. Designed to support the adoption of AI solutions, Info-Tech’s blueprint helps IT leaders enhance both patient and clinician experiences, accelerating digital transformation and driving better healthcare outcomes.

For exclusive and timely commentary from Sharon Auma-Ebanyat, an expert in the healthcare industry, and access to the complete Explore Healthcare Enterprise Large Language Model Solutions blueprint, please contact pr@infotech.com.

About Info-Tech Research Group

Info-Tech Research Group is one of the world’s leading research and advisory firms, proudly serving over 30,000 IT and HR professionals. The company produces unbiased, highly relevant research and provides advisory services to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide them with everything they need, from actionable tools to analyst guidance, ensuring they deliver measurable results for their organizations.

To learn more about Info-Tech’s divisions, visit McLean & Company for HR research and advisory services and SoftwareReviews for software buying insights.

Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com.

For information about Info-Tech Research Group or to access the latest research, visit infotech.com

SOURCE Info-Tech Research Group

https://prnmedia.prnewswire.com/news-releases/enhancing-patient-care-and-operational-efficiency-in-healthcare-with-llm-solutions-new-blueprint-from-info-tech-research-group-302271956.html

—Data Presented at the CHEST 2024 Annual Meeting—

BRIDGEWATER, N.J., Oct. 8, 2024 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Posters with the details from these subgroup analyses can be found HERE. These data were presented at the CHEST 2024 Annual Meeting, held October 6-9 in Boston, along with several other presentations from across Insmed’s respiratory portfolio.

“The positive results from the landmark Phase 3 ASPEN study have generated tremendous excitement among physicians and patients alike, providing hope for a much-needed approved treatment for bronchiectasis. Given the heterogeneity of this disease, it is striking that these new sub-analyses show a consistent positive impact on the rate of exacerbations across the majority of prespecified subgroups,” said lead study investigator James Chalmers, MBChB, Ph.D., Professor and Consultant Respiratory Physician at the School of Medicine, University of Dundee, UK. “It is particularly exciting to see that, consistent with the overall trial analysis, brensocatib 25 mg was able to slow lung function decline as measured by FEV1 for all prespecified subgroups, further underscoring the potential impact this investigational treatment candidate may have on a diverse range of patients if approved.”

Consistent with positive results for the overall ASPEN population, the annualized rate of pulmonary exacerbations favored brensocatib at both the 10 mg and 25 mg doses over placebo for almost all subgroups. In a separate analysis, least squares mean difference for brensocatib 25 mg demonstrated a reduced decline in post-bronchodilator FEV1 at Week 52 versus placebo for all prespecified subgroups. Results for patients treated with brensocatib 10 mg among subgroups were aligned with the overall trial population results.

Brensocatib was well-tolerated in the study. Treatment-emergent adverse events (TEAEs) occurring in at least 5.0% of patients treated with either dose of brensocatib and more frequently than in placebo were COVID-19 (15.8%, 20.9%, 15.8%), nasopharyngitis (7.7%, 6.3%, 7.6%), cough (7.0%, 6.1%, 6.4%), and headache (6.7%, 8.5%, and 6.9%) for brensocatib 10 mg, brensocatib 25 mg, and placebo, respectively.

“We are incredibly excited to present subgroup findings from the ASPEN study at CHEST 2024, building on the positive results we have already shared with the bronchiectasis community,” said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. “The consistency of efficacy observed across most subgroups, particularly at the higher dose, further supports our belief that brensocatib has the potential to transform the treatment landscape for patients with bronchiectasis. We eagerly look forward to filing a new drug application for brensocatib in the U.S., followed by Europe and Japan, in hopes of delivering the first approved therapy for patients affected by this serious and difficult-to-treat disease.”

Insmed plans to file a New Drug Application with the U.S. Food and Drug Administration for brensocatib in patients with bronchiectasis in the fourth quarter of 2024. Pending regulatory approvals, Insmed anticipates a U.S. launch for brensocatib in mid-2025 followed by launches in Europe and Japan in the first half of 2026. If approved, brensocatib would be the first approved treatment for patients with bronchiectasis as well as the first approved dipeptidyl peptidase 1 (DPP1) inhibitor—a new mechanism of action with the potential to address a range of neutrophil-mediated diseases.

About ASPEN

As part of the ASPEN study’s conduct, more than 460 trial sites were engaged in nearly 40 countries. After excluding sites that did not enroll any patients and all sites in Ukraine, the total number of active sites in ASPEN was 391 sites in 35 countries. Adult patients (ages 18 to 85 years) were randomized 1:1:1 and adolescent patients (ages 12 to <18 years) were randomized 2:2:1 for treatment with brensocatib 10 mg, brensocatib 25 mg, or placebo once daily for 52 weeks, followed by 4 weeks off treatment. The primary efficacy analysis included data from 1,680 adult patients and 41 adolescent patients.

About Brensocatib

Brensocatib is a small molecule, oral, reversible inhibitor DPP1 being developed by Insmed for the treatment of patients with bronchiectasis, CRSsNP, and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. Brensocatib is an investigational drug product that has not been approved for any indication in any jurisdiction.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed’s most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending three consecutive years as the No. 1 Science Top Employer. Visit www.Insmed.com to learn more.

Forward-looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “intends,” “potential,” “continues,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements.

The forward-looking statements in this press release are based upon the Company’s current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: the risk that the full data set from the ASPEN study or data generated in further clinical trials of brensocatib will not be consistent with the topline results of the ASPEN study or any additional results of the ASPEN study; failure to obtain, or delays in obtaining, regulatory approvals for brensocatib in the U.S., Europe or Japan; failure to successfully commercialize brensocatib, if approved by applicable regulatory authorities, in the U.S., Europe or Japan, or to maintain U.S., European or Japanese approval for brensocatib once approved; uncertainties in the degree of market acceptance of brensocatib by physicians, patients, third-party payors and others in the healthcare community; inaccuracies in the Company’s estimates of the size of the potential markets for brensocatib or in data the Company has used to identify physicians; expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; inability of the Company, Esteve Pharmaceuticals, S.A., Thermo Fisher Scientific, Inc. or the Company’s other third-party manufacturers to comply with regulatory requirements related to brensocatib; the Company’s inability to obtain adequate reimbursement from government or third-party payors for brensocatib or acceptable prices for brensocatib; development of unexpected safety or efficacy concerns related to brensocatib; failure to obtain regulatory approval for potential future brensocatib indications; restrictions or other obligations imposed on us by agreements related to brensocatib, including our license agreement with AstraZeneca AB, and failure to comply with our obligations under such agreements; failure to successfully conduct future clinical trials for brensocatib, including due to the Company’s potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things; risks that the Company’s clinical studies will be delayed or that serious side effects will be identified during drug development; failure of third parties on which the Company is dependent to manufacture sufficient quantities of brensocatib for commercial or clinical needs, to conduct the Company’s clinical trials, or to comply with the Company’s agreements or laws and regulations that impact the Company’s business or agreements with the Company; the strength and enforceability of the Company’s intellectual property rights or the rights of third parties; the cost and potential reputational damage resulting from litigation to which the Company may become a party, including product liability claims; changes in laws and regulations applicable to the Company’s business and failure to comply with such laws and regulations; business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises; and inability to repay the Company’s existing indebtedness and uncertainties with respect to the Company’s need and ability to access future capital.

The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company’s forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company’s business, please see the factors discussed in Item 1A, “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and any subsequent Company filings with the Securities and Exchange Commission (SEC).

The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Contact:

Investors:

Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com

Media:

Mandy Fahey
Vice President, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

SOURCE Insmed Incorporated

https://prnmedia.prnewswire.com/news-releases/new-subgroup-analyses-from-landmark-phase-3-aspen-study-of-brensocatib-in-patients-with-bronchiectasis-demonstrate-consistency-with-positive-overall-trial-population-results-302270626.html

Seattle Children’s has been named by U.S. News as the No. 1 pediatric hospital in the Pacific region and has ranked in the top 10 nationally in pediatric specialties including Cancer, Diabetes and Endocrine Disorders, Gastroenterology and GI Surgery, Nephrology, Neurology and Neurosurgery and Pulmonology.

“As the largest, independent nonprofit children’s hospital in our region, we are committed to providing the highest-quality outcomes for the children and families we serve, and it’s rewarding to see this acknowledged at a national level,” said Seattle Children’s CEO, Dr. Jeff Sperring. “Being recognized as one of the top 10 children’s hospitals in the nation is a testament to the outstanding care our teams provide and our dedication to our mission of providing hope, care, and cures.”

U.S. News, together with RTI International, collected and analyzed data from 108 children’s hospitals and surveyed thousands of pediatric specialists. Children’s hospitals awarded a “Best” designation excelled at factors such as clinical outcomes, level and quality of hospital resources directly related to patient care and expert opinion among pediatric specialists.

“For nearly two decades, U.S. News has published Best Children’s Hospitals to empower the parents and caregivers of children with complex medical needs,” said Ben Harder, chief of health analysis and managing editor at U.S. News. “Children’s hospitals appearing on the U.S. News Honor Roll have a track record of delivering unparalleled specialized care.”

The full rankings for the 2024-2025 Best Children’s Hospitals Honor Roll, regional and specialty rankings can be found at USNews.com.

MEDIA CONTACT
Sabrina Register, Manager, Public Relations
Press@seattlechildrens.org

About Seattle Children’s
Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation’s top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Foundation, along with Seattle Children’s Guild Association – the largest all volunteer fundraising network for any hospital in the country – works with our generous community to raise funds for lifesaving care and research.

For more information, visit seattlechildrens.org 

About U.S. News & World Report
U.S. News & World Report is the global leader in quality rankings that empower consumers, business leaders and policy officials to make better, more informed decisions about important issues affecting their lives and communities. A multifaceted digital media company with Education, Health, Money, Travel, Cars, News, Real Estate, Careers and 360 Reviews platforms, U.S. News provides rankings, independent reporting, data journalism, consumer advice and U.S. News Live events. More than 40 million people visit USNews.com each month for research and guidance. Founded in 1933, U.S. News is headquartered in Washington, D.C

SOURCE Seattle Children’s

https://prnmedia.prnewswire.com/news-releases/seattle-childrens-recognized-as-one-of-the-top-10-best-childrens-hospitals-in-the-us-302269626.html

MEMPHIS, Tenn., Oct. 8, 2024 /PRNewswire/ — For the 14^th consecutive year, Le Bonheur Children’s Hospital has been recognized as a 2024-2025 “Best Children’s Hospital” by U.S. News & World Report. The rankings assist parents and caregivers, along with their physicians, in navigating the challenges of choosing the best possible care for children with serious illnesses or complex medical needs.

Le Bonheur has been included in the prestigious list with recognition in eight specialties:

• Cardiology & Heart Surgery
• Gastroenterology & GI Surgery
• Neonatology
• Nephrology
• Neurology & Neurosurgery
• Orthopedics
• Pulmonology & Lung Surgery
• Urology

“For 14 years now, Le Bonheur consistently has been recognized as a ‘Best Children’s Hospital’ by U.S. News & World Report,” said Le Bonheur President and Surgeon-in-Chief Trey Eubanks, MD, FACS. “We are honored to be one of the best children’s hospitals in the country. We know that this comprehensive distinction reminds parents that their children are in the best hands when they visit Le Bonheur, and we take their trust very seriously.”

Le Bonheur is the primary pediatric hospital affiliate with the University of Tennessee Health Science Center. Together, the University of Tennessee Health Science Center and Le Bonheur train more than 350 new pediatricians and pediatric specialists each year.

U.S. News, together with RTI International, a North Carolina-based research and consulting firm, collected and analyzed data from 108 children’s hospitals and surveyed thousands of pediatric specialists. Children’s hospitals awarded a “Best” designation excelled at factors such as clinical outcomes, level and quality of hospital resources directly related to patient care and expert opinion among pediatric specialists.

“U.S. News & World Report’s annual Best Children’s Hospitals evaluation empowers parents and caregivers with a data-driven guide to help them find the best pediatric hospital to treat their child,” said Ben Harder, chief of health analysis and managing editor at U.S. News.

The full rankings for the 2024-2025 “Best Children’s Hospitals” Honor Roll, regional and specialty rankings can be found at USNews.com.

About Le Bonheur Children’s

Le Bonheur Children’s, based in Memphis, Tenn., provides expert care for children in more than 45 pediatric subspecialties, encompassing robust community programs, a pediatric research institute and regional outpatient centers in Jackson, Tenn., Tupelo, Miss., and Jonesboro, Ark. Le Bonheur also features a 290-bed hospital in Memphis and a 21-bed satellite hospital within Jackson-Madison County General Hospital in Jackson, Tenn. As the primary pediatric teaching affiliate for the University of Tennessee Health Science Center, Le Bonheur trains more than 350 pediatricians and specialists each year. Nationally recognized, Le Bonheur has been named a U.S. News & World Report Best Children’s Hospital for 14 consecutive years and is a Magnet-designated facility, the ultimate credential for high-quality patient care and nursing excellence.

For more information, please call (901) 287-6030 or visit lebonheur.org.

About U.S. News & World Report

U.S. News & World Report is the global leader in quality rankings that empower consumers, business leaders and policy officials to make better, more informed decisions about important issues affecting their lives and communities. A multifaceted digital media company with Education, Health, Money, Travel, Cars, News, Real Estate, Careers and 360 Reviews platforms, U.S. News provides rankings, independent reporting, data journalism, consumer advice and U.S. News Live events. More than 40 million people visit USNews.com each month for research and guidance. Founded in 1933, U.S. News is headquartered in Washington, D.C.

CONTACT: 
David Henson 
(423) 304-9400 
David.Henson@lebonheur.org

Ariss Arena 
(901) 283-5584 
Ariss.Arena@lebonheur.org

SOURCE Le Bonheur Children’s Hospital

https://prnmedia.prnewswire.com/news-releases/us-news–world-report-names-le-bonheur-childrens-hospital-among-best-childrens-hospitals-for-2024-2025-302270318.html